IMUC

ImmunoCellular Therapeutics, Ltd. [IMUC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IMUC Stock Summary

Top 10 Correlated Stocks

IMUC

In the News

IMUC Financial details

Company Rating
-
Market Cap
16.1M
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-0.09
Forward P/E
-
PEG
-
P/S
-
P/B
0.36
P/C
-
P/FCF
-2.72
Quick Ratio
2.81
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-6.25%
SMA50
-6.25%
SMA100
7.14%
Inst Own
-
Inst Trans
-
ROA
-264%
ROE
-344%
ROC
-4.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.11-0.4
52W High
-
52W Low
-
RSI
49.69
Rel Volume
-
Avg Volume
3.35K
Volume
Perf Week
0%
Perf Month
39.01%
Perf Quarter
93.75%
Perf Half Y
32.48%
-
-
-
-
Beta
1.192
-
-
Volatility
0%, 0%
Prev Close
0.32%
Price
0.155
Change
52.66%

Something similar

Top by Market Cap
VTI
NVDA
GOOGL
BRYN.DE
BRH.DE
Same Sector
CDXI
BLC.PA
WVE
TILS.L
6078.HK
Top Correlated Stocks
TBLT
TCCO
AFTM
SNWR
Similar Market Cap
IPDN
8455.HK
PSPW
8091.HK
USBL

Company Profile

Healthcare Biotechnology
  • Volume Average 3.35K
  • Market Capitalization 16.1M
  • Employee 3
  • CEO Dr. Irach B. Taraporewala B.S., M.S., Ph.D.
  • Headquarters Montvale,NJ,US
  • IPO Date 2021-01-08
  • Website https://www.eompharma.com

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.